VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.27 USD | +0.09% |
|
+2.20% | +11.89% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.65B |
|---|---|---|---|---|---|
| Net income 2024 * | -452M | Net income 2025 * | -507M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-17.5
x | P/E ratio 2025 * |
-16.2
x | Employees | 254 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vaxcyte, Inc.
More recommendations
More press releases
More news
| 1 day | +0.09% | ||
| 1 week | +2.20% | ||
| 1 month | +16.05% | ||
| 3 months | -4.81% | ||
| 6 months | +35.73% | ||
| Current year | +11.89% |
1 week
67.21
71.61
1 month
63.1176.00
Current year
53.8382.04
1 year
44.2082.04
3 years
16.7882.04
5 years
15.5182.04
10 years
15.5182.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Fairman
FOU | Founder | 60 | 13-05-26 |
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
| Director of Finance/CFO | 55 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
Anne Drapeau
BRD | Director/Board Member | 57 | 21-09-15 |
Heath Lukatch
BRD | Director/Board Member | 56 | 18-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.27% | 0 M€ | 0.00% | - | |
| 0.10% | 0 M€ | 0.00% | - | |
| 0.08% | 1,487 M€ | +7.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 70.27 | +0.09% | 525,672 |
| 24-05-30 | 70.21 | +3.37% | 827,232 |
| 24-05-29 | 67.92 | -1.14% | 362,562 |
| 24-05-28 | 68.7 | -0.09% | 439,691 |
| 24-05-24 | 68.76 | -0.74% | 480,352 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
70.27
USD
Average target price
103.1
USD
Spread / Average Target
+46.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.89% | 7.65B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- PCVX Stock
